Is the gut the "sweet spot" for the treatment of diabetes?

Diabetes

Volumn 63, Issue 7, 2014, Pages 2225-2228

  Rubino, Francesco ^a   Amiel, Stephanie A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN;

ADRENAL GLAND; BYPASS SURGERY; CELL GROWTH; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPERTENSION; HYPOPHYSIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTESTINE; LEUKEMIA REMISSION; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; GASTRIC BYPASS; INSULIN; INSULIN-SECRETING CELLS; MALE; OBESITY, MORBID;

EID: 84903128504     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0402     Document Type: Note

References (30)

1. Luft R. Oskar Minkowski: discovery of the pancreatic origin of diabetes, 1889. Diabetologia 1989;32:399-401
2. Welbourn R. The History of Endocrine Surgery. New York, Praeger Publishers, 1990
3. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-1585
4. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-1576
5. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240-2249
6. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:56265
7. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1-11 (Pubitemid 38176365)
8. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
9. Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 2014;63:1725-1737
10. Salinari S, Bertuzzi A, Guidone C, Previti E, Rubino F, Mingrone G. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg 2013;257:462-468
11. Dirksen C, Bojsen-Møller KN, Jørgensen NB, et al. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 2013;56:2679-2687
12. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013;36:2175-2182
13. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353:249-254 (Pubitemid 41058324)
14. Li Z, Zhang HY, Lv LX, et al. Roux-en-Y gastric bypass promotes expression of PDX-1 and regeneration of beta-cells in Goto-Kakizaki rats. World J Gastroenterol 2010;16:2244-2251
15. Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenal-jejunal bypass protects GK rats from beta-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab 2011;300:E923-E932
16. Guimarães M, Rodrigues P, Gonçalves G, Nora M, Monteiro MP. Heterotopic pancreas in excluded stomach diagnosed after gastric bypass surgery. BMC Surg 2013;13:56
17. Lindqvist A, Spégel P, Ekelund M, et al. Gastric bypass improves β-cell function and increases β-cell mass in a porcine model. Diabetes 2014;63:1665-1671
18. Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of β-cell mass. Ann N Y Acad Sci 2010;1212:41-58
19. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010;59:1765-1770
20. Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 de ficiency. Mol Metab 2013;3:1912201
21. Shah M, Law JH, Micheletto F, et al. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 2014;63:483- 493
22. Salinari S, le Roux CW, Bertuzzi A, Rubino F, Mingrone G. Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes 2014;63:1069-1078
23. Patel RT, Shukla AP, Ahn SM, Moreira M, Rubino F. Surgical control of obesity and diabetes: the role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity (Silver Spring) 2014;22:159-169
24. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-559 (Pubitemid 35246885)
25. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008;31(Suppl. 2):S290-S296
26. Patti ME, Goldfine AB. Hypoglycemia after gastric bypass: the dark side of GLP-1. Gastroenterology 2014;146:605-608
27. Salinari S, Debard C, Bertuzzi A, et al. Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance. PLoS One 2013;8:e56258
28. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 26 March 2014 [Epub ahead of print]
29. Breen DM, Rasmussen BA, Côté CD, Jackson VM, Lam TK. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes 2013;62: 3005-3013
30. Saeidi N1, Meoli L, Nestoridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science. 2013;341:406-410